Skip to content

Exploring the Role of Magnesium in Rest Cramps

Magnesium Status & Effect of Magnesium Infusions on Rest Cramps

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00423540
Enrollment
54
Registered
2007-01-18
Start date
2007-01-31
Completion date
2008-11-30
Last updated
2008-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rest Cramps

Keywords

magnesium infusion, magnesium sulfate, rest cramps, nocturnal leg cramps, muscle cramps, fractional urinary excretion, urinary excretion, 24 hour urine, serum magnesium, magnesium deficiency, family practice, general practice, richmond, cramp frequency, magnesium status, urinary magnesium, cramp diary, sf 36

Brief summary

This study sets out to show whether infusions of magnesium can lessen the frequency of rest cramps and to determine whether rest cramp sufferers have a deficiency in magnesium.

Detailed description

Subjects will be randomized to receive 5 days of 4 hour IV infusions of D5W either with or without 20 mmol magnesium sulfate added. Twenty four hour urinary excretion of magnesium will be determined on the first day of infusions to assess whether magnesium deficiency is present. Ten normal controls will also undergo a single infusion and collection of urine to serve as a comparison group for the urinary excretion data.

Interventions

DRUGIntravenous Infusion of Magnesium Sulfate

See Detailed Description.

Sponsors

Vancouver Coastal Health Research Institute
CollaboratorOTHER
University of British Columbia
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* ≥2 leg or foot cramps per week in a 4 week run-in diary

Exclusion criteria

* eGFR\<50 * Neurologic disease * Pregnancy * Heart block * Bradyarhythmia without pacemaker * Digoxin use * Liver disease * Addison's disease * History of MI * CHF * Absence of detectable reflexes

Design outcomes

Primary

MeasureTime frame
Change in the frequency of leg cramps per week (active versus placebo) over the first 30 days post infusions compared to the 30 days prior to randomization (as recorded in patient diaries).See above

Secondary

MeasureTime frame
Assessment of magnesium status at trial entry as determined by 24 hour fractional excretion of magnesium on day 1 of infusions.
Subjective assessment as to whether cramps were unchanged, more, or less frequent /painful/bothersome over the 3 months. following infusions.See above
Overall quality of life changes as measured by an SF36 questionnaire.

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026